日韩黄色一级片免费看-丁香婷婷激情五月天综合-日日激情综合久久一区-久久麻豆精亚洲av品国产一区

  設(shè)為主頁 加入收藏 English
 
 
 
 新聞動(dòng)態(tài)
 行業(yè)動(dòng)態(tài)
 展會(huì)信息
 誠聘英才
 
 

Nanobrook Omni測(cè)量應(yīng)用案例-15

發(fā)布時(shí)間:2018-06-20  點(diǎn)擊次數(shù):227  新聞來源:
 

文獻(xiàn)名: Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease

 

作者Jennifer L.Schneider, Robert K.Dingman, Sathy V.Balu-Iyer

Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214

 

摘要:Enzyme replacement therapy with recombinant human acid α-glucosidase (rhGAA) is complicated by the formation of anti-rhGAA antibodies, a short circulating half-life, instability in the plasma, and limited uptake into target tissue. Previously, we have demonstrated that phosphatidylinositol (PI) containing liposomes can reduce the immunogenicity and extend plasma survival of factor VIII (FVIII) in a mouse model of hemophilia A. In this article, we investigate the ability of PI liposomes to be used as a delivery vehicle to overcome the issues that complicate therapy with rhGAA. In a murine model of Pompe disease, administration of PI-rhGAA mitigated the immunogenicity of rhGAA, resulting in a significantly lower formation of anti-rhGAA antibodies. PI-rhGAA also showed minimal improvements to the pharmacokinetic parameters and efficacy measures compared to free rhGAA. Overall, these data suggest that PI-rhGAA may have the potential to be a useful therapeutic option for improving the treatment of Pompe disease.

 
 
上海市普陀區(qū)嵐皋路567號(hào)1108-26室 電話:021-62665073 400-718-7758 傳真:021-62761957
美國布魯克海文儀器公司上海代表處 版權(quán)所有  管理登陸 ICP備案號(hào):滬ICP備19006074號(hào)-2 技術(shù)支持:化工儀器網(wǎng)